JPRN-jRCT1080223563已完成未知
Consideration of ZOREDORON acid to an osteoporosis patient and the validity of the vitamin D medicine manufacturing use
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable(—)
- 性别
- All
入选标准
- •I make the patient who fills all following standards the subject.
- •1) Japanese Society for Bone and Mineral Research A nuclear power plant, based on the check standard of the osteoporosis (revise in fiscal year 2012), a nuclear power plant, the patient diagnosed as osteoporosis.
- •2) the age of the time of the agreement merit, more than 20-year-old patient (I don't ask about the gender.)
- •3) the patient who is after menopause since putting it for the lady
- •4) the patient who could get documentary consent by free will of the back and the patient person himself which had the enough explanation in case of participation of this research
排除标准
- •The patient who conflicts in following one of them won't incorporate in this research.
- •1) the patient who has treatment reki of osteoporosis before agreement acquisition
- •2) patient with peptic ulcer
- •3) patient with abnormality of severe blood
- •4) patient with severe hepatopathy
- •5) patient with severe kidney trouble (patient of a creatinine clearance 35mL/min sheep rise)
- •6) patient with a severe heart malfunction
- •7) patient with operating during dental disposal or infection in the active mouth
- •8) the patient who has that in a dehydrating state (high fever, the high loose bowels and vomit, etc.)
- •9) patient of a hypocalcemia
- •10) patient with the medical history of the severe drug allergy
- •11) patient with aspirin asthma or its medical history
- •12) the female with during pregnancy or a pregnant possibility or lactating woman
- •13) additionally the patient who judged that a study person in charge was unsuitable as a subject of research person
研究者
相似试验
进行中(未招募)
1 期
Zoledronic acid in patients with metastatic prostate cancer treated with abiraterone acetate: impact on bone mineral densityMetastatic castration-resistant prostate cancerMedDRA version: 18.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001146-34-FRCentre Oscar Lambret
已完成
4 期
Effect of zoledronic acid on osteoporosis for the chronic stroke patientsD020521strokeJPRN-jRCT1031190091Fujiwara Toshiyuki
进行中(未招募)
不适用
Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or endocrine treatment - ProBONE IIEUCTR2004-002832-24-DEovartis Pharma GmbH
进行中(未招募)
不适用
Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment - ProBONE IEUCTR2004-002831-14-DEovartis Pharma GmbH
Unknown
不适用
Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke PatientsStrokeNCT04652128Yonsei University56
